Study #2021-0111
A Phase 1, Multicenter, Open-Label, Dose Finding Study of CC-96673 in Subjects with Relapsed or Refractory Non-Hodgkin's Lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
CC-96673
Description
The purpose of this Phase 1 study is to evaluate the safety and tolerability of CC-96673 in adult participants with Relapsed or Refractory Non-Hodgkin's Lymphoma (R/R NHL). The study will be conducted in 2 parts: Part A, monotherapy dose escalation and Part B, monotherapy dose expansion.
Information and next steps
Disease:
Lymphoma, Non-Hodgkin
Study phase:
I
Physician name:
Paolo Strati
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.